Tags

Type your tag names separated by a space and hit enter

Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats.
Brain Res. 2005 Jun 28; 1048(1-2):138-45.BR

Abstract

Orexins A and B are a pair of neuropeptides implicated in the regulation of feeding and arousal behavior mediated through two orexin receptors type 1 and type 2. We have determined the arousal effects of newly developed selective orexin receptor type 2 agonist, [Ala11]orexin-B, on the sleep-wake cycle in rats. The effects of third ventricle intracerebroventricular (ICV) infusion of the novel orexin receptor type 2 selective agonist, [Ala11]orexin-B, on the sleep-wake cycle were investigated. ICV infusion of [Ala11]orexin-B (1, 10 and 40 nmol) during the light period (11:00-16:00) dose-dependently resulted in a significant increase in wake duration by 46.9% (n = 5, P < 0.05), 159.2% (n = 4, P < 0.01) and 163.6% (n = 7, P < 0.01)), respectively, and a significant decrease in rapid eye movement (REM) (P < 0.01) and non-REM sleep (P < 0.01) for all doses. In contrast, ICV infusion of orexin B at the same doses (1, 10 and 40 nmol) caused a 16.6% (n = 6, non-significant), 99.8% (n = 6, P < 0.05) and 72.0% (n = 4, P < 0.05) increase in wakefulness, respectively. Moreover, orexin-A, which exerts its effects through orexin receptor type 1 and orexin receptor type 2 with similar potency, resulted in a significant increase in wakefulness duration by 17.1% (n = 6, P < 0.05), 184.0% (n = 6, P < 0.01) and 228.6% (n = 6, P < 0.01) at doses of 0.1, 1 and 10 nmol, respectively. Further, the enhancement of wakefulness was accompanied by a marked reduction in REM and non-REM sleep. These findings suggest that orexin receptor type 2 plays an important role in the modulation of sleep-wake state and behavioral responses.

Authors+Show Affiliations

Department of Biosystem Regulation, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15919057

Citation

Akanmu, Moses A., and Kazuki Honda. "Selective Stimulation of Orexin Receptor Type 2 Promotes Wakefulness in Freely Behaving Rats." Brain Research, vol. 1048, no. 1-2, 2005, pp. 138-45.
Akanmu MA, Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res. 2005;1048(1-2):138-45.
Akanmu, M. A., & Honda, K. (2005). Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Research, 1048(1-2), 138-45.
Akanmu MA, Honda K. Selective Stimulation of Orexin Receptor Type 2 Promotes Wakefulness in Freely Behaving Rats. Brain Res. 2005 Jun 28;1048(1-2):138-45. PubMed PMID: 15919057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. AU - Akanmu,Moses A, AU - Honda,Kazuki, PY - 2005/02/09/received PY - 2005/04/20/revised PY - 2005/04/22/accepted PY - 2005/5/28/pubmed PY - 2005/9/15/medline PY - 2005/5/28/entrez SP - 138 EP - 45 JF - Brain research JO - Brain Res VL - 1048 IS - 1-2 N2 - Orexins A and B are a pair of neuropeptides implicated in the regulation of feeding and arousal behavior mediated through two orexin receptors type 1 and type 2. We have determined the arousal effects of newly developed selective orexin receptor type 2 agonist, [Ala11]orexin-B, on the sleep-wake cycle in rats. The effects of third ventricle intracerebroventricular (ICV) infusion of the novel orexin receptor type 2 selective agonist, [Ala11]orexin-B, on the sleep-wake cycle were investigated. ICV infusion of [Ala11]orexin-B (1, 10 and 40 nmol) during the light period (11:00-16:00) dose-dependently resulted in a significant increase in wake duration by 46.9% (n = 5, P < 0.05), 159.2% (n = 4, P < 0.01) and 163.6% (n = 7, P < 0.01)), respectively, and a significant decrease in rapid eye movement (REM) (P < 0.01) and non-REM sleep (P < 0.01) for all doses. In contrast, ICV infusion of orexin B at the same doses (1, 10 and 40 nmol) caused a 16.6% (n = 6, non-significant), 99.8% (n = 6, P < 0.05) and 72.0% (n = 4, P < 0.05) increase in wakefulness, respectively. Moreover, orexin-A, which exerts its effects through orexin receptor type 1 and orexin receptor type 2 with similar potency, resulted in a significant increase in wakefulness duration by 17.1% (n = 6, P < 0.05), 184.0% (n = 6, P < 0.01) and 228.6% (n = 6, P < 0.01) at doses of 0.1, 1 and 10 nmol, respectively. Further, the enhancement of wakefulness was accompanied by a marked reduction in REM and non-REM sleep. These findings suggest that orexin receptor type 2 plays an important role in the modulation of sleep-wake state and behavioral responses. SN - 0006-8993 UR - https://www.unboundmedicine.com/medline/citation/15919057/Selective_stimulation_of_orexin_receptor_type_2_promotes_wakefulness_in_freely_behaving_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-8993(05)00644-X DB - PRIME DP - Unbound Medicine ER -